drugset
drugset / Trial / NCT04629976

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976 ↗

Phase 1 Completed 21 enrolled Nucorion Pharmaceuticals, Inc. Ligand Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).

Timeline

Start
2021-01-12
Primary completion
2022-09-30
Completion
2022-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject NCO-48 Fumarate Unknown 4 mg Oral
Subject NCO-48 Fumarate Unknown 20 mg Oral
Comparator tenofovir alafenamide Small molecule 25 mg Oral

Indications

chronic hepatitis B virus infection